The BiosecureAct in the US could be a game-changer for Indian CRAMs players like Divis

ICICID says the US' Biosecure Act which seeks to restrict Chinese biotech cos operating in the US could provide a significant opportunity for Indian CRAMs players like Divis, Syngene. CRAMs industry is $7B & growing at 14% CAGR. Biosecure Act could further accelerate this growth https://twitter.com/ICICI_Direct/status/1828435544512074023

[IMG]